Dr. Patricia LoRusso

Dr. Patricia LoRusso is Associate Director of Developmental Therapeutics, Yale Cancer Center.  Dr. LoRusso has been a practicing academic medical oncologist performing clinical/translational research in early phase clinical trials for over 30 years. She has had continuous NIH/NCI peer review funding for 28 years, having held a U-grant for early phase clinical trials through the NCI Cancer Therapy Evaluation Program (CTEP) for 26 years. She has also collaborated on numerous other grants and have been an investigator in P01 and P30 funding mechanisms. Understanding the need for team science, she has participated in P50 mechanisms and has been awarded team science grants through such organizations as Stand Up to Cancer (Co-Leader: Melanoma Dream Team), the Department of Defense (DOD) and the Komen Foundation (Co-leader, KG111063: Targeting Stem Cells in Triple-Negative Breast Cancer (TNBC) in Different Racial Populations). Dr. LoRusso has also been involved in many service disciplines at the NCI. In addition, Dr. LoRusso has served in leadership positions of several other organizations, including the Board of Directors and numerous scientific and education committees of the American Association for Cancer Research (AACR), the education and scientific committees of the American Society of Clinical Oncology (ASCO), and the steering committee for the Food and Drug Administration (FDA) Accelerating Anticancer Agent Development and Validation Workshop. She has worked closely with Cancer Research United Kingdom (CRUK), a UK Welcome Trust – the second largest funding agency for cancer research. She is currently serving a 3-year term as the chair of their New Agents Committee (NAC). Working closely over the past 3 decades with patients suffering from advanced malignancies, Dr. LoRusso has become an advocate, not only for cancer researchers and clinicians, but more importantly for the patients and their caregivers. Having experienced at a young age the death of her own parents from cancer, she understands the urgent need for new cancer discoveries and the potential for longevity and quality of life.
The Actuate SAB was established to shepherd the development and advancement of Actuate’s best-in-class GSK-3β inhibitors into and through clinical trials in patients with advanced cancer. With elraglusib (9-ING-41),  Actuate’s lead program, advancing into Phase 2 and registration path clinical trials, the Advisory Board will play a larger role in advising on target diseases for prioritization and clinical trial design.